Status: Recruiting
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
Participants needed: 67
Trial details
Phase: Phase 3Age: 20+Biological sex: AllType: InterventionalSponsor: PharmaEssentia Japan K.K.Updated: Nov 8, 2024Locations: 6
Eligibility criteria
Patients who have completed the 52-week treatment duration in Study A19-201 and... [+1]
Patients who are considered by the investigator or sub investigator to be inelig...